Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

42 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +41 more
Locations
  • Mayo Clinic Hospital ( Site 0140) Scottsdale, Arizona, United States
  • UCLA Hematology & Oncology ( Site 0017) Los Angeles, California, United States
  • Colorado Blood Cancer Institute ( Site 0225) Denver, Colorado, United States
  • University of Michigan ( Site 0018) Ann Arbor, Michigan, United States
View Trial Details
Active, not recruiting

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

NCT04904588

Conditions
Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, +30 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Stanford University Stanford, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 39 locations
View Trial Details
Active, not recruiting

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

NCT02952508

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Central Nervous System Lymphoma, +36 more
Locations
  • Cellectar Biosciences site Los Angeles, California, United States
  • Cellectar Biosciences site Redlands, California, United States
  • Cellectar Biosciences site Washington D.C., District of Columbia, United States
  • Cellectar Biosciences site Jacksonville, Florida, United States
View all 52 locations
View Trial Details
Completed

DPX-Survivac and Checkpoint Inhibitor in DLBCL

NCT03349450

Conditions
Adult Diffuse Large Cell Lymphoma, Adult Refractory Diffuse Large B-Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, +18 more
Locations
  • Tom Baker Cancer Centre - Alberta Health Services Calgary, Alberta, Canada
  • Nova Scotia Health Authority: Queen Elizabeth II Health Sciences Centre Halifax, Nova Scotia, Canada
  • London Health Sciences Centre London, Ontario, Canada
  • Ottawa Hospital Research Institute Ottawa, Ontario, Canada
View Trial Details
Completed

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

NCT02393859

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Research Site Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
  • Research Site Randwick, New South Wales, Australia
  • Research Site Westmead, New South Wales, Australia
  • Research Site South Brisbane, Queensland, Australia
View all 103 locations
View Trial Details
Completed

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

NCT05804032

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Universitätsklinikum Krems Krems, Austria
  • Ordensklinikum Linz Linz, Austria
  • Landeskrankenhaus Feldkirch-Rankweil Rankweil, Austria
  • Universitätsklinikum der Paracelsus, 3. Med. Abteilung/Onkologie Ambulanz Salzburg, Austria
View all 91 locations
View Trial Details
Completed

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

NCT05228470

Conditions
BCMA, BCMA-CD3 Bispecific, Bispecific, +23 more
Locations
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Guangdong Provincial People's Hospital Guangzhou, Guangdong, China
  • Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
View all 15 locations
View Trial Details

Related conditions